


Contineum Therapeutics, Inc. (CTNM)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001855175

Contineum Therapeutics, Inc.		
CTNM; healthcare		
Grade	None 3 of 14 inputs computable; 7 are required	Share price, twelve months to the rescansplit-adjusted close; the letter is fixed at the rescans that set it 
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025	
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$120M to \$591M assets total assets \$276.6M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	short runway, thin data, degenerate inputs not computable: dilution, distress, fortress balance sheet	
Inputs computable	3 of 14	
Graded from	filings received through Mar 5, 2026 218 days before the rescans; latest periodic filing 10-Q received Jul 30, 2026	
Last close	\$13.21 2026-10-08; market equity \$305.1M	
Price used in grade	None	

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease. We focus on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical-stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications. We are developing PIPE-307 in collaboration with J&J.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 76.8						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.9%)	(6.6%)	76.8	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 2.3						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		19.89	(0.31)	2.8	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		27.50x	2.96x	1.8	839	2025-12-31
Growth and financing						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 1
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		not computable	2.1%			four annual observations are required; found 2
Net share issuance, one year		not computable	2.5%			two annual share counts are required; found 1

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.3 months
Thin data	3 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	38.2%	8.0%	70
Distance from 52-week high	(25.0%)	(31.4%)	58
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(18.2%)	(1.0%)	24
Book value to price	0.79	0.28	80
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.11	(0.14)	70

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$14.7M
Operating cash flow, four quarters	-\$53.0M
Months of runway	3.3
Days since last periodic filing	71 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	\$6.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$60.0M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$55.3M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
3	assets	us-gaap:Assets	\$276.6M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
4	assets	us-gaap:Assets	\$212.8M	2024-12-31	2026-03-05	10-K	0001628280-26-015165
5	current assets	us-gaap:AssetsCurrent	\$267.9M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
6	current liabilities	us-gaap:LiabilitiesCurrent	\$9.7M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$177.4M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
8	operating income	us-gaap:OperatingIncomeLoss	-\$68.1M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
9	book equity	us-gaap:StockholdersEquity	\$261.0M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
10	liabilities	us-gaap:Liabilities	\$15.7M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2024-12-31	2025-03-06	10-K	0001437749-25-006458
12	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$231,000	2025-12-31	2026-03-05	10-K	0001628280-26-015165
13	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$323,000	2025-12-31	2026-03-05	10-K	0001628280-26-015165
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$50.4M	2025-12-31	2026-03-05	10-K	0001628280-26-015165
15	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-05	10-K	0001628280-26-015165
16	current assets	us-gaap:AssetsCurrent	\$206.4M	2024-12-31	2026-03-05	10-K	0001628280-26-015165
17	current liabilities	us-gaap:LiabilitiesCurrent	\$10.0M	2024-12-31	2026-03-05	10-K	0001628280-26-015165
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,871,549	2025-02-28	2025-03-06	10-K	0001437749-25-006458